Actively Recruiting
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Led by Vanda Pharmaceuticals · Updated on 2025-02-20
100
Participants Needed
3
Research Sites
98 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.
CONDITIONS
Official Title
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with gastroparesis
- Demonstrated delayed gastric emptying
- Presence of moderate to severe nausea
- Body Mass Index (BMI) of 6518 and 6540 kg/m2
You will not qualify if you...
- Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
- A positive test for drugs of abuse at the screening or evaluation visits
- Pregnancy or nursing
- Evidence of uncontrolled blood glucose (including HbA1C >11% at screening or metabolic crisis in past 60 days)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Vanda Investigational Site
Leuven, Belgium, 3000
Actively Recruiting
2
Vanda Investigational Site
Liège, Belgium, 4000
Actively Recruiting
3
Vanda Investigational Site
Leipzig, Germany, 04103
Actively Recruiting
Research Team
V
Vanda Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here